References

Al-Mariri, A., N.H. Mahmoud and R. Hammoud, 2012. Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice. Biologicals, 40: 140-145.
CrossRef  |  

Arenas-Gamboa, A.M., T.A. Ficht, M.M. Kahl-McDonagh, G. Gomez and A.C. Rice-Ficht, 2009. The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun., 77: 877-884.
PubMed  |  

Backert, S. and T.F. Meyer, 2006. Type IV secretion systems and their effectors in bacterial pathogenesis. Curr. Opin. Microbiol., 9: 207-217.
CrossRef  |  

Carle, A., C. Hoppner, A.K. Ahmed, Q. Yuan, A. den Dulk-Ras et al., 2006. The brucella suis type IV secretion system assembles in the cell envelope of the heterologous host Agrobacterium tumefaciens and increases IncQ plasmid pLS1 recipient competence. Infect. Immun., 74: 108-117.
PubMed  |  

Cassataro, J., K.A. Pasquevich, S.M. Estein, D.A. Laplagne and A. Zwerdling et al., 2007. A DNA vaccine coding for the chimera BLOSmp31 induced a better degree of protection against B. ovis and similar degree of protection against B. melitensis than review. 1 vaccination. Vaccine, 25: 5958-5967.
PubMed  |  

Chen, J., S.Y. Huang, Z.Y. Li, Z.G. Yuan and D.H. Zhou et al., 2013. Protective immunity induced by a DNA vaccine expressing eIF4A of Toxoplasma gondii against acute toxoplasmosis in mice. Vaccine, 31: 1734-1739.
CrossRef  |  

Commander, N.J., J.M. Brewer, B.W. Wren, S.A. Spencer, A.P. MacMillan and J.A. Stack, 2010. Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge. Genet. Vaccines Ther., Vol. 8. 10.1186/1479-0556-8-5

De Amorim, J., A. Magalhaes, J.E. Munhoz, G.M. Rittner, J.D. Nosanchuk, L.R. Travassos and C.P. Taborda, 2013. DNA vaccine encoding peptide P10 against experimental paracoccidioidomycosis induces long-term protection in presence of regulatory T cells. Microbes Infect., 15: 181-191.
CrossRef  |  

Den Hartigh, A.B., H.G. Rolan, M.F. de Jong and R.M. Tsolis, 2008. VirB3 to VirB6 and VirB8 to VirB11, but not VirB7, are essential for mediating persistence of Brucella in the reticuloendothelial system. J. Bacteriol., 190: 4427-4436.
CrossRef  |  

Donnelly, J.J., J.B. Ulmer, J.W. Shiver and M.A. Liu, 1997. DNA vaccines. Life Sci., 15: 617-648.
Direct Link  |  

Ge, G., S. Wang, Y. Han, C. Zhang, S. Lu and Z. Huang, 2012. Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine. PLoS ONE, Vol. 7. 10.1371/journal.pone.0041573

Golding, B., D.E. Scott, O. Scharf, L.Y. Huang and M. Zaitseva et al., 2001. Immunity and protection against Brucella abortus. Microbes Infect., 3: 43-48.
CrossRef  |  PubMed  |  Direct Link  |  

Hu, X.D., S.T. Chen, J.Y. Li, D.H. Yu, Yi-Zhang and H. Cai, 2010. An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8⁺ cytotoxic T cell response. Vaccine, 28: 2408-2415.
CrossRef  |  

Jain-Gupta, N., A. Contreras-Rodriguez, R. Vemulapalli, S.G. Witonsky, S.M. Boyle and N. Sriranganathan, 2012. Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice. FEMS Immunol. Med. Microbiol., 66: 436-444.
CrossRef  |  

Kahl-Mcdonagh, M.M. and T.A. Ficht, 2006. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect. Immun., 74: 4048-4057.
Direct Link  |  

Kaushik, P., D.K. Singh, S.V. Kumar, A.K. Tiwari, G. Shukla, S. Dayal, P. Chaudhuri, 2010. Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides. Vet. Res. Commun., 34: 119-132.
PubMed  |  

Kurar, E. and G.A. Splitter, 1997. Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine, 15: 1851-1857.
CrossRef  |  PubMed  |  

Luo, D., B. Ni, P. Li, W. Shi and S. Zhang et al., 2006. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infect. Immun., 74: 2734-2741.
CrossRef  |  Direct Link  |  

Luo, D.Y., P. Li, L. Xing, G.Y. Zhao, W. Shi, S.L. Zhang and X.L. Wang, 2006. DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. Chin. Med. J., 119: 331-334.

Nagai, H., 2010. Structure and function of the type IV secretion systems of bacterial pathogens. Nihon Saikingaku Zasshi, 65: 379-386 (In Japanese).
PubMed  |  Direct Link  |  

Onate, A.A., S. Cespedes, A. Cabrera, R. Rivers and A. Gonzalez et al., 2003. A DNA Vaccine encoding Cu, Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun., 71: 4857-4861.
Direct Link  |  

Paredes-Cervantes, V., R. Flores-Mejia, M.C. Moreno-Lafont, H. Lanz-Mendoza and A.T. Tello-Lopez et al., 2011. Comparative proteome analysis of Brucella abortus 2308 and its virB type IV secretion system mutant reveals new T4SS-related candidate proteins. J. Proteomics, 74: 2959-2971.
CrossRef  |  PubMed  |  

Perkins, S.D., S.J. Smither and H.S. Atkins, 2010. Towards a Brucella vaccine for humans. FEMS Microbiol. Rev., 34: 379-394.
CrossRef  |  Direct Link  |  

Rittner, G.M., J.E. Munoz, A.F. Marques, J.D. Nosanchuk, C.P. Taborda and L.R. Travassos, 2012. Therapeutic DNA vaccine encoding peptide P10 against experimental paracoccidioidomycosis. PLoS Neglected Trop. Dis., Vol. 6. 10.1371/journal.pntd.0001519

Roodbari, F., F. Sabahi, M.N. Sarbolouki, F. Barkhordari, A. Adeli, A. Jamedar and F. Mahboudi, 2012. Immune responses against a new HIV-1 p24-gp41/pCAGGS-IL-12 DNA vaccine in Balb/c mice. Iran. J. Immunol., 9: 86-97.
Direct Link  |  

Rouot, B., M.T. Alvarez-Martinez, C. Marius, P. Menanteau and L. Guilloteau et al., 2003. Production of the type IV secretion system differs among Brucella species as revealed with VirB5- and VirB8-specific antisera. Infect. Immunity, 71: 1075-1082.
CrossRef  |  Direct Link  |  

Siqueira, I.M., A.M. Ribeiro, Y.K. de Medeiros Nobrega, K.S. Simon and A.C.O. Souza et al., 2012. DNA-hsp65 vaccine as therapeutic strategy to treat experimental chromoblastomycosis caused by Fonsecaea pedrosoi. Mycopathologia, 10.1007/s11046-012-9599-7

Sivanesan, D., M.A. Hancock, G.A. Villamil and C. Baron, 2010. Quantitative analysis of VirB8-VirB9-VirB10 interactions provides a dynamic model of type IV secretion system core complex assembly[J]. Biochemistry, 49: 4483-4493.
CrossRef  |  Direct Link  |  

Studier, FW., 2005. Protein production by auto-induction in high density shaking cultures. Protein Exp. Purif., 41: 207-234.
Direct Link  |  

Terradot, L., R. Bayliss, C. Oomen, G.A. Leonard, C. Baron and G. Waksman, 2005. Structures of two core subunits of the bacterial type IV secretion system, VirB8 from Brucella suis and ComB10 from Helicobacter pylori. Proc. Natl. Acad. Sci., 102: 4596-4601.
CrossRef  |  

Velikovsky, C.A., J. Cassataro, G.H. Giambartolomei, F.A. Goldbaum and S. Estein et al., 2002. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun., 70: 2507-2511.
CrossRef  |  

Villamil, G.A., D. Sivanesan, A. Carle, A. Paschos and M.A. Smith et al., 2012. Type IV secretion system core component VirB8 from brucella binds to the globular domain of VirB5 and to a periplasmic domain of VirB6[J]. Biochemistry, 51: 3881-3890.
CrossRef  |  Direct Link  |  

Waksman, G. and R. Fronzes, 2010. Molecular architecture of bacterial type IV secretion systems. Trends Biochem. Sci., 35: 691-698.
CrossRef  |  

Wallden, K., A. Rivera-Calzada and G. Waksman, 2010. Type IV secretion systems: Versatility and diversity in function. Cell. Microbiol., 12: 1203-1212.
CrossRef  |  

Wang, P.Y., Z.G. Yuan, E. Petersen, J. Li and X.X. Zhang et al., 2012. Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice. Clin. Vaccine Immunol., 19: 1916-1920.
CrossRef  |  Direct Link  |  

Xin, X., 1986. Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine. Vaccine, 4: 212-216.
PubMed  |  

Xu, J., W. Xu, X. Chen, D. Zhao and Y. Wang, 2008. Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice. Vaccine, 26: 4519-4525.
CrossRef  |  

Yu, D.H., M. Li, X.D. Hu and H. Cai, 2007. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Vaccine, 25: 6744-6754.
PubMed  |  

Yu, D.H., X.D. Hu, H. Cai and M. Li, 2007. A combined DNA vaccine encoding BCSP31, SOD and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA Cell Biol., 26: 435-443.
CrossRef  |